Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
144.88
+1.15 (0.80%)
Oct 12, 2026, 4:00 PM EDT - Market closed
Protagonist Therapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Reiterates $150 → $190 | Buy | Reiterates | $150 → $190 | +31.14% | Oct 12, 2026 |
| UBS No rating | UBS | Buy Initiates $184 | Buy | Initiates | $184 | +27.00% | Oct 12, 2026 |
| Citi | Citi | Buy Maintains $175 → $182 | Buy | Maintains | $175 → $182 | +25.62% | Sep 10, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $186 | Buy | Maintains | $186 | +28.38% | Sep 1, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $149 | Buy | Reiterates | $149 | +2.84% | Sep 1, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 1, 2026 |
| Barclays | Barclays | Buy Maintains $153 → $180 | Buy | Maintains | $153 → $180 | +24.24% | Sep 1, 2026 |
| Clear Street | Clear Street | Buy Maintains $173 | Buy | Maintains | $173 | +19.41% | Sep 1, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.